BridgeBio Pharma (BBIO) Revenue & Revenue Breakdown
BridgeBio Pharma Revenue Highlights
Latest Revenue (Y)
$221.90M
Latest Revenue (Q)
$108.11M
Main Segment (Y)
License
Main Geography (Y)
License
BridgeBio Pharma Revenue by Period
BridgeBio Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $221.90M | 2285.27% |
| 2023-12-31 | $9.30M | -88.02% |
| 2022-12-31 | $77.65M | 11.38% |
| 2021-12-31 | $69.72M | 745.14% |
| 2020-12-31 | $8.25M | -79.66% |
| 2019-12-31 | $40.56M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
BridgeBio Pharma generated $221.90M in revenue during NA 2024, up 2285.27% compared to the previous quarter, and up 547.10% compared to the same period a year ago.
BridgeBio Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $108.11M | -2.22% |
| 2025-06-30 | $110.56M | -5.20% |
| 2025-03-31 | $116.63M | 1882.88% |
| 2024-12-31 | $5.88M | 115.30% |
| 2024-09-30 | $2.73M | 26.01% |
| 2024-06-30 | $2.17M | -98.97% |
| 2024-03-31 | $211.12M | 11998.57% |
| 2023-12-31 | $1.75M | -57.35% |
| 2023-09-30 | $4.09M | 149.30% |
| 2023-06-30 | $1.64M | -10.13% |
| 2023-03-31 | $1.83M | -2.35% |
| 2022-12-31 | $1.87M | 453.25% |
| 2022-09-30 | $338.00K | -99.54% |
| 2022-06-30 | $73.75M | 4253.36% |
| 2022-03-31 | $1.69M | -86.85% |
| 2021-12-31 | $12.89M | 449.74% |
| 2021-09-30 | $2.34M | -95.66% |
| 2021-06-30 | $54.02M | 11593.51% |
| 2021-03-31 | $462.00K | 278.69% |
| 2020-12-31 | $122.00K | -98.50% |
| 2020-09-30 | $8.13M | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $13.82M | -48.32% |
| 2019-09-30 | $26.74M | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
BridgeBio Pharma generated $108.11M in revenue during Q3 2025, up -2.22% compared to the previous quarter, and up 4986.67% compared to the same period a year ago.
BridgeBio Pharma Revenue Breakdown
BridgeBio Pharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|
| Product | $3.79M | - | - |
| License | $65.92M | $8.00M | $13.80M |
BridgeBio Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 21: License (94.56%), and Product (5.44%).
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 | Mar 25 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | $4.28M | - | - | - | - | - | - | - | - | - |
| License and Service | $8.31M | $1.83M | $338.00K | $73.75M | - | - | - | - | - | - |
| Product | $108.11M | - | - | $1.46M | $759.00K | $987.00K | - | - | - | - |
| Royalty Revenue | - | $1.62M | - | - | - | - | - | - | - | - |
| Net Product Revenue | - | $71.50M | $36.74M | - | - | - | - | - | - | - |
| License | - | - | - | - | - | - | $235.00K | $1.58M | $8.00M | - |
BridgeBio Pharma's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Product (89.57%), License and Service (6.89%), and Royalty (3.54%).
BridgeBio Pharma Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 19 |
|---|---|
| License | $13.80M |
BridgeBio Pharma's latest annual revenue breakdown by geography, as of Dec 19: License (100.00%).
Quarterly Revenue by Country
| Country | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Sep 20 |
|---|---|---|---|---|---|---|---|
| License and Service | $1.83M | $338.00K | $73.75M | - | - | - | - |
| Product | - | - | - | $1.46M | $759.00K | $987.00K | - |
| License | - | - | - | $235.00K | $1.58M | $8.00M | - |
BridgeBio Pharma's latest quarterly revenue breakdown by geography, as of Mar 23: License and Service (100.00%).
BridgeBio Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals | $4.07B | $1.05B |
| MRNA | Moderna | $3.24B | $1.02B |
| BMRN | BioMarin Pharmaceutical | $2.85B | $776.13M |
| EXEL | Exelixis | $2.17B | $597.75M |
| IONS | Ionis Pharmaceuticals | $705.14M | $156.72M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| BBIO | BridgeBio Pharma | $221.90M | $108.11M |
| ROIV | Roivant Sciences | $124.80M | $1.57M |
| RNA | Avidity Biosciences | $10.90M | $12.47M |
| RVMD | Revolution Medicines | - | - |
| SMMT | Summit Therapeutics | - | - |